Equine & Livestock

Fall/Winter 2022 Equine & Livestock Solutions

Issue link: https://www.e-digitaleditions.com/i/1478196

Contents of this Issue


Page 20 of 43

Equine protozoal myeloencephalitis (EPM) is a devastating disease. Fortunately, with ReBalance, you don't have to make trade-offs between efficacy and affordable treatment. In clinical trials, 61.5% of horses given ReBalance were considered treatment successes 1 , and the efficacy of approved treatments is comparable. 2 For your cost-conscious clients, prescribe FDA-approved ReBalance. Contact your PRN Pharmacal sales representative or preferred distributor for more information. Or call 800-874-9764 and visit www.prnpharmacal.com/rebalance. (sulfadiazine and pyrimethamine) Antiprotozoal Oral Suspension Tough on EPM. Gentle on the wallet. 1 Animal Health Pharmaceuticals. Freedom of information summary, NADA 141–240. REBALANCE Antiprotozoal Oral Suspension (sulfadiazine and pyrimethamine) "for the treatment of horses with equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona." Animal Health Pharmaceuticals, LLC, St. Joseph, MO; 2004. 2 Johnson AL. Evidence-Based Review of Diagnosis and Treatment of Sarcocystis neurona Infection (Equine Protozoal Myeloencephalitis), in Proceedings. 55th Annual American Association of Equine Practitioners Convention 2009; 172-176. ©2015 Pegasus Laboratories, Inc. PRN® and ReBalance® are all trademarks of Pegasus Laboratories, Inc. REB-8/15-02 Important Safety Information For use in horses only. Do not use in horses intended for human consumption. Not for human use. Keep out of the reach of children. Prior to treatment with ReBalance Antiprotozoal Oral Suspension, EPM should be distinguished from other diseases that may cause ataxia in horses. Injuries or lameness may also complicate the evaluation of an animal with EPM. In most instances, ataxia due to EPM is asymmetrical and affects the front and/or the hind limbs. Treatment may cause generalized bone marrow suppression, anemia, leukopenia, neutropenia, and thrombocytopenia. A complete blood count (CBC) should be performed monthly to monitor horses for development of these conditions. The administration of the drug may need to be discontinued and/or treatments for bone marrow suppression initiated. Other, less frequent side effects included decreased appetite, loose stools, and mild colic. In most cases, the gastrointestinal signs were self-limiting and did not require discontinuation of treatment. Worsened neurologic deficits (treatment crisis) may be observed during a period beginning with the first few days of treatment with ReBalance and ranging out to 5 weeks. This neurologic deficit exacerbation may be the result of an inflammatory reaction to the dying parasites in the CNS tissue. The safe use of ReBalance Antiprotozoal Oral Suspension in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated. The safety of ReBalance with concomitant therapies in horses has not been evaluated. ReBalance is not for use in horses with known hypersensitivity to sulfonamide drugs or pyrimethamine. Refer to the prescribing information for complete details or visit prnpharmacal.com/rebalance.

Articles in this issue

Links on this page

Archives of this issue

view archives of Equine & Livestock - Fall/Winter 2022 Equine & Livestock Solutions